Status: Recruiting
Engineered Dendritic Cell Vaccines for Multiple Myeloma
The purpose of this study is to determine the feasibility, safety, and efficacy of dendritic cell (DC) vaccines in the treatment of multiple myeloma (MM) or plasmacytoma based on immune-modified DC vaccines (DCvac). This approach is aimed to achieve prolonged maintenance of remission in multiple myeloma or plasmacytoma patients.
Participants needed: 10
Trial details
Phase: Phase 1Age: 18-80Biological sex: AllType: InterventionalSponsor: Shenzhen Geno-Immune Medical InstituteUpdated: Jun 23, 2026Locations: 1
Eligibility criteria
Male and female subjects with multiple myeloma or plasmacytoma [+4]
Pregnant or lactating women [+3]